Article Details

AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal

Retrieved on: 2024-03-19 19:52:03

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal. View article details on hiswai:

Summary

AstraZeneca's acquisition of Fusion Pharmaceuticals for $2.4bn enhances its oncology portfolio with radioconjugates, a targeted cancer treatment, positioning it alongside competitors like Novartis in the pharmaceutical industry and leveraging business intelligence for strategic growth.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up